-
Hymon® Pan-Cancer Screening Test Kit
The Pan-Cancer Screening Test uses gene methylation and other HymonBio’s patented technologies on the PCR platform to detect up to 28 types of cancer in blood samples.
-
HAEMOCERT™ Colorectal Cancer Screening Test
HAEMOCERT™ Colorectal Cancer Screening Test has passed CE certification and is used for early colorectal cancer screening. Tests for 3 gene methylation and 1 gene mutation. -
Hymon® Urine Bladder Cancer Screening
HymonBio Bladder Cancer Gene Methylation Detection Kit is used to detect specific gene methylation of exfoliated cells in urine. This kit uses innovative multi-gene detection technology, combined with original NPC Nucleic Acid Extraction technology to better protect the integrity of cellular DNA and greatly improve sensitivity and specificity. The sensitivity was 92%, and the specificity was 94%. The kit uses non-invasive urine samples, making testing convenient and improves compliance, and providing a non-invasive technical means for monitoring recurrence after clinical treatment.
-
Hymon® Blood Gastric Cancer Screening
HymonBio Gastric Cancer Gene Methylation Detection Kit uses 2 specific gene methylation of circulating tumor DNA (cfDNA) in blood samples. This kit uses innovative multi-gene detection technology, combined with original Magnetic Bead Extraction technology improving efficiency of low-concentration small fragment cell-free nucleic acid, and hence has higher sensitivity and specificity; clinical studies have shown a sensitivity of 89% and specificity of 91%. The kit uses non-invasive blood samples, making testing convenient and improves compliance, and providing a non-invasive technical means for monitoring recurrence after clinical treatment.
-
Hymon® BCR-ABL Tyrosine Kinase Gene Detection Kit
This kit uses RT-PCR to detect breakpoint cluster region-abelson leukemia (BCR-ABL) fusion gene in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clincial evaluation fo defined BCR-ABL fusion gene in chronic myeloid leukemia patients. Confirmed mutation: recommended therapies include imatinib, treatment options and drug efficacy evaluation.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
-
Hymon® IDH1, IDH2 and FLT3 Gene Mutation Detection Kit
This kit uses RT-PCR to detect human isocitrate dehydrogenase (IDH1 and IDH2) and FMS-like tyrosine kinase 3 (FLT3) gene mutations in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined IDH1, IDH2 and FLT3 gene mutations in acute myeloid leukemia (AML) patients. Confirmed mutation: recommended medications include ivosidenib, enasidenib, gilteritinib, midostaurin
The test uses specific gene sequences as PCR target regions. Human genomic sequence is used as internal quality control.
-
Hymon® BRAF Gene Mutation Detection Kit
This kit uses RT-PCR to detect v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutations in plasma or formalin-fixed paraffin-embedded tissue (FFPE) samples. Test results may serve as a reference for clincial evaluation of defined BRAF gene mutations in melanoma and non-small-cell lung cancer (NSCLC) patients. Confirmed mutation: recommended medications include dabrafenib, vemurafenib, trametinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
-
Hymon® RET Gene Mutation Detection Kit
This kit uses RT-PCR to detect rearranged during trasfection (RET) M918T, C634Y, and C634R mutations in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined human RET gene mutations in targeted drug use and drug resistance for non-small cell lung cancer (NSCLC). Confirmed mutation: recommended medications include pratinib, selpercatinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human geonomic sequence is used as internal quality control.
-
Hymon® MET Gene Mutation Detection Kit
This kit uses RT-PCR to detect human mesenchymal-epithelial transition factor (MET) gene mutations in peripheral blood or formalin-fixed paraffin-embedded tissue (FFPE) samples. Targeted medication for non-small cell lung cancer (NSCLC). Confirmed mutation: recommended medications include savolitinib, gumetinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
-
Hymon® ROS1 Fusions Gene Detection Kit
This kit uses RT-PCR to detect recombinant c-ros oncogene 1 (ROS1) fusion gene in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined ROS1 fusion gene in non-small-cell lung cancer (NSCLC) patients. Confirmed mutation: recommended medications include emtricinib, crizotinib, ceritinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
-
Hymon® EML4-ALK Fusion Gene Detection Kit
This kit uses RT-PCR to detect echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined EML4-ALK fusion gene in non-small-cell lung cancer (NSCLC) patients. Confirmed mutation: recommended medications include crizotinib, ceritinib, alectinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
-
Hymon® EGFR Gene Mutation Detection Kit
This kit uses RT-PCR to detect epidermal growth factor receptor (EGFR) gene mtuation in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined EGFR gene mutations in non-small-cell lung cancer (NSCLC) patients. Confirmed mutation: recommended medications include gefitinib, afatinib, dacomitinib, erlotinib, osimertinib, etc.
The test uses specific gene sequences as target regions. Human genomic sequence is used as internal quality control.
